Clinically, CAR-T cells targeting CD19 and other B-cell antigens have achieved notable success in relapsed/refractory B-cell malignancies, spurring exploration of CAR-T therapy in AIDs, including systemic lupus erythematosus (SLE), where CD19-targeted CAR-T cells have reduced anti-dsDNA antibodies with no notable adverse events reported (3). This evidence concerns the gene CD19 and systemic lupus erythematosus.